Baseline echocardiographic variables as predictors of hemodynamically significant cytokine release syndrome in adults treated with CD19 CAR T-cell therapy for hematological malignancies

Bibliographic Details
Title: Baseline echocardiographic variables as predictors of hemodynamically significant cytokine release syndrome in adults treated with CD19 CAR T-cell therapy for hematological malignancies
Authors: Andres E. Daryanani, Muhannad A. Abbasi, Maria F. Gomez Ardila, Eduardo Tellez-Garcia, Juan M. Garzon-Dangond, Yi Lin, Jonas Paludo, Joerg Herrmann, Stephen M. Ansell, Allison C. Rosenthal, Hector R. Villarraga
Source: Cardio-Oncology, Vol 10, Iss 1, Pp 1-11 (2024)
Publisher Information: BMC, 2024.
Publication Year: 2024
Collection: LCC:Diseases of the circulatory (Cardiovascular) system
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: Echocardiography, Chimeric antigen T-cell therapy, B-cell lymphoma, Cytokine release syndrome, Cancer therapy-related cardiac dysfunction, Cardiotoxicity, Diseases of the circulatory (Cardiovascular) system, RC666-701, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: Abstract Background CD19 CAR T-cell therapy is a novel anti-cancer treatment that has produced remarkable responses in relapsed or refractory B-cell hematological malignancies. Cytokine Release Syndrome (CRS) is a dysregulated immune response that frequently occurs after CAR T-cell infusion. It can cause cardiac dysfunction and circulatory collapse negatively impacting outcomes and survival. To endure the insults of CRS, patients are typically screened for adequate cardiac reserve before treatment. The relationship between baseline cardiac function by echocardiography and the development of moderate to severe presentations of CRS is unclear. Methods This study aimed to identify baseline echocardiographic variables that can predict the development of hemodynamically significant CRS (CRS ≥ 2), evaluate their behavior at follow-up, and investigate the incidence of cancer therapy-related cardiac dysfunction (CTRCD). An observational retrospective cohort study of patients treated with CD19 CAR T-cell therapy with a baseline echocardiogram was performed. Demographic, clinical and echocardiographic variables were abstracted from the electronic health record. Patients were grouped and compared by the occurrence of CRS
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2057-3804
Relation: https://doaj.org/toc/2057-3804
DOI: 10.1186/s40959-024-00290-6
Access URL: https://doaj.org/article/87cebc1b5f8047e184905b24b3b31df9
Accession Number: edsdoj.87cebc1b5f8047e184905b24b3b31df9
Database: Directory of Open Access Journals
More Details
ISSN:20573804
DOI:10.1186/s40959-024-00290-6
Published in:Cardio-Oncology
Language:English